Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Ultragenyx (NASDAQ:RARE) announced that president and CEO Emil Kakkis, M.D., Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 4:00 PM ET.
A live and archived webcast will be available on Ultragenyx’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – RARE
In the Jun 4 session, RARE gained 4.02%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.7% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 22 | Inducement grant | Neutral | -1.1% | Inducement RSU grant to 11 newly hired non-executive officers. |
| May 06 | Conference participation | Neutral | +0.8% | Participation in Bank of America’s 2026 Healthcare Conference fireside chat. |
| May 05 | Earnings results | Positive | +3.7% | Q1 2026 results with $136M revenue and reaffirmed 2026 guidance and milestones. |
| Apr 29 | Earnings call setup | Neutral | -1.4% | Announcement of May 5, 2026 conference call for Q1 2026 results. |
| Apr 24 | Inducement grant | Neutral | -0.5% | Inducement RSU grant of 36,447 shares to new non-executive officers. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent operational and housekeeping news (conference participation, inducement grants) has generally been met with modest single-day moves, while the Q1 2026 earnings and corporate update drew the strongest positive reaction.
Over the last few months, Ultragenyx has mixed routine corporate updates with more material milestones. Inducement grants on Apr 24 and May 22, 2026 led to small negative moves. Conference-related announcements on Apr 29 and May 6, 2026 produced modest reactions. The key event was the May 5, 2026 Q1 2026 earnings report, which showed $136M revenue, reaffirmed $730–$760M 2026 guidance, and outlined a path to profitability in 2027, resulting in a 3.68% gain. Today’s Goldman Sachs conference participation fits the pattern of routine investor-relations outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET.
The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
